Effects of fluconazole singly and in combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal meningoencephalitis in an intracranial murine model

被引:8
作者
Hossain, MA [1 ]
Mukherjee, PK [1 ]
Reyes, G [1 ]
Long, L [1 ]
Ghannoum, MA [1 ]
机构
[1] Univ Hosp Cleveland, Dept Dermatol, Ctr Med Mycol, Cleveland, OH 44106 USA
关键词
cryptococcosis; animal model; high dose fluconazole; combination therapy;
D O I
10.1179/joc.2002.14.4.351
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study we developed a highly reproducible intracranial murine model of cryptococcosis. Mice (Balb/c, 5-7 weeks old) were challenged intracranially and treated with intermediate (30 mg/kg) or high (90 mg/kg) dose fluconazole, and amphotericin B (0.75 mg/kg), administered singly or in combination with flucytosine (100 mg/kg). Survival and brain CFU analyses were performed. Effect of fluconazole prophylaxis was also determined. Our data show that the developed model mimics clinical signs of cryptococcal meningitis. In single treatment, fluconazole (30 mg/kg) was more efficacious than amphotericin B or flucytosine (P <0.0001). Combination treatment led to significantly increased anticryptococcal activity, which was highest for high dose fluconazole + flucytosine (P <0.0001). However, no significant difference was observed between high dose fluconazole treatment with and without flucytosine (P >0.05). Fluconazole prophylaxis led to a significant decrease in brain CFU. In conclusion, high dose fluconazole administered post-infection, or as prophylaxis, may be highly efficacious in the treatment and prevention of meningoencephalitis.
引用
收藏
页码:351 / 360
页数:10
相关论文
共 48 条
[21]   PHARMACOKINETICS OF FLUCONAZOLE IN CEREBROSPINAL-FLUID AND SERUM OF RABBITS - VALIDATION OF AN ANIMAL-MODEL USED TO MEASURE DRUG CONCENTRATIONS IN CEREBROSPINAL-FLUID [J].
MADU, A ;
CIOFFE, C ;
MIAN, U ;
BURROUGHS, M ;
TUOMANEN, E ;
MAYERS, M ;
SCHWARTZ, E ;
MILLER, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (09) :2111-2115
[22]   The changing face of AIDS-related opportunism: Cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review [J].
Manfredi, R ;
Pieri, F ;
Pileri, SA ;
Chiodo, F .
MYCOPATHOLOGIA, 1999, 148 (02) :73-78
[23]  
Manorot M, 2000, INT J CLIN PHARM TH, V38, P355
[24]   Opportunistic infections occurring during highly active antiretroviral treatment [J].
Michelet, C ;
Arvieux, C ;
François, C ;
Besnier, JM ;
Rogez, JP ;
Breux, JP ;
Souala, F ;
Allavena, C ;
Raffi, F ;
Garre, M ;
Cartier, F .
AIDS, 1998, 12 (14) :1815-1822
[25]   MONOCLONAL-ANTIBODIES TO CRYPTOCOCCUS-NEOFORMANS GLUCORONOXYLOMANNAN ENHANCE FLUCONAZOLE EFFICACY [J].
MUKHERJEE, J ;
FELDMESSER, M ;
SCHARFF, MD ;
CASADEVALL, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1398-1405
[26]   Reintroduction of the PLB1 gene into Candida albicans restores virulence in vivo [J].
Mukherjee, PK ;
Seshan, KR ;
Leidich, SD ;
Chandra, J ;
Cole, GT ;
Ghannoum, MA .
MICROBIOLOGY-SGM, 2001, 147 :2585-2597
[27]   An alternative animal model for comparison of treatments for cryptococcal meningitis [J].
Najvar, LK ;
Bocanegra, R ;
Graybill, JR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :413-414
[28]   The exciting future of antifungal therapy [J].
Neely, MN ;
Ghannoum, MA .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (12) :897-914
[29]   Combination therapy with fluconazole and flucytosine in the murine model of Cryptococcal meningitis [J].
Nguyen, MH ;
Najvar, LK ;
Yu, CY ;
Graybill, JR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1120-1123
[30]   PRIMARY PROPHYLAXIS WITH FLUCONAZOLE AGAINST SYSTEMIC FUNGAL-INFECTIONS IN HIV-POSITIVE PATIENTS [J].
NIGHTINGALE, SD ;
CAL, SX ;
PETERSON, DM ;
LOSS, SD ;
GAMBLE, BA ;
WATSON, DA ;
MANZONE, CP ;
BAKER, JE ;
JOCKUSCH, JD .
AIDS, 1992, 6 (02) :191-194